middl
east
respiratori
syndrom
coronaviru
merscov
first
identifi
saudi
arabia
soon
first
report
import
case
occur
mani
countri
outsid
arabian
peninsula
infect
travel
notabl
outbreak
south
korea
clinic
sign
merscovinfect
patient
similar
sever
acut
respiratori
syndrom
coronaviru
sarscov
outbreak
china
caus
acut
respiratori
distress
syndrom
human
bat
dromedari
consid
natur
reservoir
merscov
continu
increas
human
case
endem
area
report
highlight
urgent
develop
make
avail
effect
therapeut
drug
prophylact
vaccin
protect
merscov
date
mani
promis
approach
toward
merscov
vaccin
candid
develop
recombin
viral
vector
proteinbas
platform
bacterialbas
platform
dna
vaccin
merscov
vaccin
candid
focus
major
immunedomin
antigen
protein
virion
play
signific
role
mediat
viral
entri
target
cell
induc
neutral
antibodi
experiment
anim
infect
individu
receptorbind
domain
rbd
within
domain
protein
merscov
viru
decid
host
rang
cellular
tropism
develop
two
promis
merscov
vaccin
candid
use
two
differ
platform
one
use
rabi
viru
rv
vector
express
domain
merscov
gene
develop
recombin
merscov
vaccin
appli
gramposit
enhanc
matrix
gem
particl
vector
construct
mer
bacterium
lactococcu
lacti
like
particl
blp
vaccin
display
rbd
previou
studi
util
rv
vector
modifi
rv
vaccin
vector
spbn
success
design
vaccin
merscov
infect
wherea
rv
vector
strain
use
studi
screen
street
alabama
dufferin
sad
strain
plaqu
purif
babi
syrian
hamster
kidney
cell
cell
proven
safe
good
immunogen
gempa
system
novel
surfac
display
system
consist
nonliv
genet
unmodifi
gem
particl
protein
anchor
pa
lactococcu
lacti
peptidoglycan
hydrolas
acma
util
system
success
display
rbd
protein
fragment
merscov
induc
high
neutral
antibodi
intramuscular
vaccin
robust
antigenspecif
local
system
immun
respons
intranas
vaccin
headtohead
comparison
avail
vaccin
vector
necessari
vaccin
design
differ
immun
respons
induc
two
differ
merscov
vaccin
candid
effect
antigen
display
viral
bacteri
vector
immun
respons
still
question
studi
evalu
immunolog
efficaci
mer
blp
differ
dose
inactiv
recombin
mer
antigen
bablc
mice
specif
compar
abil
two
vaccin
induc
merscovspecif
humor
immun
respons
tcellmedi
immun
respons
well
neutral
antibodi
merscov
anim
work
strictli
accord
welfar
ethic
guidanc
chines
laboratori
anim
gb
agreement
approv
anim
welfar
ethic
committe
institut
veterinari
medicin
changchun
veterinari
research
institut
laboratori
anim
care
use
committe
author
permit
number
babi
syrian
hamster
kidney
cell
cultur
serumfre
medium
shanghai
china
orbit
shaker
rpm
suspens
cultur
viru
infect
mous
neuroblastoma
na
cell
cultur
dulbecco
modifi
eagl
medium
dmem
thermo
fisher
scientif
waltham
usa
plu
fetal
bovin
serum
fb
biolog
industri
kibbutz
beit
haemek
israel
determin
viral
titer
verif
viru
inactiv
spodoptera
frugiperda
gibco
grand
island
ny
usa
insect
cell
grown
ii
medium
life
technolog
san
diego
ca
usa
protein
express
recombin
rv
express
merscov
protein
rvmer
construct
store
laboratori
rvmer
viru
cultiv
cell
briefli
cell
cell
per
ml
grown
shake
flask
cultur
infect
rvmer
viru
multipl
infect
moi
rvmer
harvest
cultur
supernat
cell
cultur
two
day
postinfect
dpi
titer
recombin
viru
determin
median
endpoint
tissu
cultur
infecti
dose
unit
na
cell
describ
previous
recombin
viru
inactiv
vv
mixtur
incub
overnight
treat
h
verif
viru
complet
inactiv
detect
na
cell
complet
inactiv
viru
purifi
hollow
fiber
ultrafiltr
column
sepharos
fast
flow
gel
fraction
harvest
analyz
immunoblot
total
protein
concentr
purifi
product
determin
bicinchonin
acid
bca
protein
assay
mer
blp
produc
previous
describ
briefli
fusion
protein
express
baculoviru
express
system
gem
particl
use
vector
construct
mer
blp
extern
display
rbd
fusion
protein
concentr
mer
blp
detect
densitometr
use
quantiti
one
imag
analysi
softwar
version
size
hydrodynam
diamet
nm
size
distribut
polydispers
index
pdi
rvmer
mer
blp
determin
use
laser
particl
size
analyz
nano
malvern
instrument
worcestershir
uk
fresh
prepar
rvmer
mer
blp
suspens
determin
almost
humid
temperatur
sampl
measur
perform
triplic
simultan
four
sixweekold
femal
balbc
mice
purchas
changchun
yisi
laboratori
anim
technolog
co
ltd
changchun
china
femal
balbc
mice
random
five
group
mice
intramuscularli
primeimmun
purifi
rvmer
viru
mer
blp
mix
compound
adjuv
consist
seppic
pari
franc
poli
c
sigma
st
loui
mo
usa
boost
twice
equal
volum
antigen
primari
vaccin
interv
compound
adjuv
immun
neg
control
blood
sampl
collect
immun
two
week
vaccin
serum
sampl
inactiv
min
determin
merscov
rbdspecif
antibodi
neutral
antibodi
five
mice
select
randomli
group
euthan
day
third
immun
splenocyt
collect
cytokin
analysi
enzymelink
immunosorb
assay
elisa
appli
analyz
merscov
rbdspecif
igg
antibodi
serial
dilut
sera
ad
microtit
plate
corningcostar
corn
ny
usa
precoat
overnight
mersrbd
protein
produc
escherichia
coli
plate
incub
h
wash
three
time
pbst
incub
follow
horseradish
peroxidas
hrp
label
antimous
igg
bioworld
st
loui
mn
usa
southern
biotech
birmingham
al
usa
h
plate
wash
three
time
tmb
per
well
ad
color
develop
stop
ad
optic
densiti
valu
read
nm
use
elisa
plate
reader
biorad
hercul
ca
usa
neutral
titer
mice
sera
detect
use
merscov
pseudoviru
report
previou
studi
briefli
serial
dilut
mous
sera
mix
equal
volum
merspseudotyp
virus
incub
min
mixtur
incub
huh
cell
h
incub
medium
replac
complet
dmem
contain
fetal
bovin
serum
sampl
incub
h
luciferas
activ
detect
use
infinit
micropl
spectrophotomet
tecan
switzerland
evalu
antigenspecif
tcell
respons
splenocyt
harvest
day
third
immun
stimul
merscov
peptid
h
secret
tumor
necrosi
factoralpha
interferongamma
interleukin
supernat
detect
mous
elisa
cytokin
kit
mabtech
nacka
sweden
statist
analysi
perform
use
graphpad
softwar
result
express
mean
sd
signific
differ
group
analyz
use
student
ttest
particl
size
polydispers
index
rvmer
mer
blp
measur
dynam
light
scatter
dl
devic
immun
mice
shown
figur
size
rvmer
nm
figur
size
mer
blp
nm
figur
compar
immunolog
efficaci
two
merscov
vaccin
deriv
two
differ
vector
studi
impact
immunogen
merscov
blp
differ
dose
immunogen
rvmer
one
certain
dose
mice
schemat
diagram
group
design
immun
immunolog
character
shown
figur
total
five
group
mice
administ
three
immun
combin
adjuv
intramuscular
im
rout
immun
pb
neg
control
immun
inactiv
purifi
rvmer
immun
low
dose
medium
dose
high
dose
merscov
blp
respect
sequenti
sera
sampl
collect
week
detect
neutral
activ
pseudotyp
merscov
bind
activ
splenocyt
harvest
week
last
immun
cytokin
analysi
shown
figur
develop
neutral
antibodi
respons
week
first
immun
neutral
antibodi
detect
point
howev
neutral
antibodi
significantli
higher
week
immun
also
signific
differ
neutral
activ
among
indic
merscov
blp
effici
induc
merscov
neutral
antibodi
mice
overal
result
show
rvmer
rapidli
induc
neutral
antibodi
respons
mer
blp
induc
higher
antibodi
respons
mice
next
detect
merscov
rbdspecif
igg
igg
subtyp
antibodi
level
serum
week
postimmun
elisa
result
indic
mer
antigeninduc
igg
antibodi
specif
bind
merscov
rbd
protein
particularli
acquir
stronger
bind
merscov
rbd
protein
wherea
control
sampl
detect
neglig
bind
activ
figur
indic
specif
igg
antibodi
respons
induc
rbd
protein
addit
endpoint
titer
igg
antibodi
level
show
immunogen
much
stronger
induc
merscov
rbdspecif
igg
antibodi
respons
mice
three
vaccin
figur
furthermor
signific
differ
shown
igg
titer
among
group
suggest
antigen
protein
bacteri
vector
suffici
induc
high
rbdspecif
antibodi
level
mice
thu
merscov
antigen
protein
display
surfac
bacteri
vector
significantli
enhanc
immunogen
rbd
fragment
helper
respons
associ
helper
respons
correl
mice
order
evalu
igg
subtyp
level
serum
immun
mice
product
sera
detect
observ
sera
igg
subtyp
show
sera
induc
significantli
higher
level
antibodi
figur
sera
induc
significantli
higher
level
antibodi
figur
c
signific
differ
antibodi
level
figur
sera
induc
significantli
higher
level
antibodi
figur
howev
analysi
ratio
reveal
sera
remark
higher
figur
collect
result
suggest
merscov
antigen
protein
display
surfac
viral
vector
appear
induc
stronger
immun
respons
bacteri
vector
next
order
analyz
merscov
specif
tcell
immun
respons
detect
level
secret
splenocyt
restimul
mer
peptid
level
significantli
higher
suggest
antigen
protein
bacteri
vector
suffici
induc
potent
tcell
respons
wherea
level
remark
higher
week
postimmun
wpi
figur
result
indic
merscov
antigen
protein
display
viral
vector
induc
superior
cellular
immun
respons
bacteri
vector
merscov
continu
infect
human
caus
morbid
mortal
sinc
sever
outbreak
caus
potenti
global
merscov
pandem
howev
prophylact
therapeut
avail
protect
mer
current
licens
although
research
develop
test
sever
merscov
vaccin
candid
mani
anim
model
candid
vaccin
sever
advantag
challeng
preexist
immun
immunogen
costeffect
develop
two
promis
merscov
vaccin
candid
use
two
differ
platform
one
recombin
rv
express
merscov
protein
fragment
use
gem
particl
vector
display
merscov
rbd
protein
fragment
studi
compar
humor
cellular
respons
balbc
mous
model
result
indic
rvmer
vaccin
induc
rapidli
neutral
antibodi
stronger
tcell
immun
respons
merscov
blp
vaccin
howev
merscov
blp
vaccin
induc
higher
level
neutral
antibodi
rvmer
vaccin
two
uniqu
aspect
highlight
studi
first
rv
vector
besid
merscov
proven
success
util
mani
emerg
infecti
diseas
ebola
viru
ebov
lassa
viru
lasv
marburg
viru
marv
human
immunodefici
viru
type
lymphocyt
choriomening
viru
lcmv
addit
ebola
viru
vaccin
close
clinic
trial
notabl
chemic
inactiv
rabi
viru
vaccin
wide
use
vaccin
human
dog
cat
ferret
show
safe
human
anim
therefor
inactiv
rabi
virusbas
vaccin
also
safe
induc
neutral
antibodi
target
pathogen
result
show
inactiv
rabi
viru
vector
safe
immunogen
profil
anim
highlight
promis
vaccin
develop
second
uniqu
aspect
studi
gempa
system
novel
surfac
display
system
flexibl
effect
costeffect
easytohandl
altern
heterolog
protein
display
gem
particl
gem
particl
lactococcu
lacti
boil
acid
mainli
contain
bacterialshap
peptidoglycan
sphere
lack
cell
compon
addit
lactococcu
lacti
safe
appli
food
recent
year
gembas
vaccin
recogn
safe
furthermor
gem
particl
proven
enhanc
immun
respons
carrier
display
antigen
high
densiti
adjuv
vaccin
develop
gem
particl
also
improv
humor
cellular
immun
respons
activ
matur
dendrit
cell
enhanc
antigenpres
capac
stimul
dc
produc
cytokin
besid
peptidoglycan
main
compon
gem
particl
tolllik
receptor
tlr
ligand
moreov
gem
particl
effici
bind
antigen
protein
room
temperatur
obtain
purifi
protein
onestep
centrifug
process
conveni
econom
scale
vaccin
develop
gem
particl
also
bind
differ
antigen
protein
particl
develop
multival
vaccin
system
success
display
varieti
heterolog
protein
pathogen
show
strong
antigenspecif
immun
respons
parenter
vaccin
mucos
vaccin
includ
virus
bacteria
parasit
studi
result
suggest
rbd
protein
merscov
display
gem
particl
could
induc
strong
humor
cellular
immun
respons
even
dose
low
two
vaccin
platform
studi
advantag
disadvantag
rvbase
merscov
vaccin
platform
rapidli
induc
antibodi
immun
respons
higher
cellular
immun
respons
gembas
vaccin
platform
howev
risk
incomplet
inactiv
process
inactiv
rvmer
addit
rvmer
vaccin
need
purifi
mani
purif
step
factor
must
consid
vaccin
product
antigen
protein
densiti
distribut
particl
two
key
paramet
elicit
effici
immun
respons
vaccin
design
high
densiti
order
antigen
array
display
particl
make
bind
event
host
bcell
surfac
immunoglobulin
particl
occur
easili
import
step
induc
sequenti
immun
respons
gembas
vaccin
platform
could
display
antigen
protein
high
densiti
rvbase
vaccin
platform
display
antigen
protein
also
express
rv
gp
protein
may
gembas
vaccin
merscov
induc
much
stronger
humor
immun
respons
mice
rvbase
vaccin
microparticl
could
promot
humor
immun
respons
nanoparticl
much
easier
induc
cellular
immun
respons
size
rvmer
virion
nm
diamet
mer
blp
particl
nm
may
critic
factor
induc
differ
cellular
immun
respons
two
differ
vector
vaccin
platform
specif
molecul
microbi
origin
intrins
innat
immun
trigger
endow
adjuv
activ
lipopolysaccharid
lp
bacteri
lipopeptid
deoxyribonucl
acid
dna
ribonucl
acid
rna
conserv
molecul
receptor
molecul
mammalian
tolllik
receptor
tlr
member
tlr
confirm
cell
surfac
membran
membran
endosom
peptidoglycan
main
compon
gem
particl
tlr
ligand
activ
receptor
human
peripheralblood
mononuclear
cell
induc
immun
respons
singl
strand
rna
compon
inactiv
rabi
viru
tlr
ligand
agonist
shown
polar
effect
immun
respons
differ
receptor
play
import
role
deliv
differ
signal
host
cell
activ
antigen
present
cell
apc
precis
defin
natur
perceiv
danger
send
inform
secondari
lymphoid
organ
induc
relev
adapt
immun
respons
may
anoth
ignor
factor
induc
differ
immun
respons
immun
system
think
danger
viru
infect
bacteri
infect
immun
system
trigger
combin
event
stimuli
vaccin
immunolog
compound
adjuv
contain
emuls
polyi
c
tlr
ligand
may
anoth
assign
caus
speed
antibodi
product
cellular
immun
respons
need
improv
futur
studi
gembas
vaccin
platform
solv
problem
tri
screen
optimum
adjuv
vaccin
codisplay
proteinadjuv
gem
particl
flagellin
tlr
ligand
furthermor
gembas
vaccin
platform
may
suitabl
develop
mucos
vaccin
consid
lactococcu
lacti
safe
use
probiot
food
understand
mode
action
gembas
vaccin
platform
allow
us
design
much
safer
costeffect
protect
vaccin
desir
immun
respons
goal
studi
test
vaccin
vector
headtohead
comparison
immunogen
two
merscov
vaccin
candid
might
use
real
vaccin
human
anim
studi
provid
import
refer
select
suitabl
vaccin
platform
develop
merscov
vaccin
special
pathogen
studi
